<DOC>
	<DOCNO>NCT01333813</DOCNO>
	<brief_summary>This study evaluate persistence immunity hepatitis B healthy child age 7 8 year , previous vaccination Infanrix hexa™ first two year life , also ability mount immune response challenge dose Engerix-B™ Kinder .</brief_summary>
	<brief_title>Hepatitis B Antibody Persistence Immune Response Hepatitis B Vaccine Challenge Previously Vaccinated Children</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Hepatitis B Antibodies</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . A male female 7 8 year age time enrolment . Subjects document evidence previous vaccination four consecutive dos Infanrix hexa™ part routine vaccination Germany : three dos primary vaccination receive 9 month age one booster dose receive 11 18 month age . Written inform consent obtain parents/Legally Acceptable Representative ( ) subject time enrolment . In addition inform consent sign parent ( ) /Legally Acceptable Representative ( ) , write informed assent subject seek subject judge able understand investigator . Healthy subject establish medical history clinical examination enter study . Child care Use investigational nonregistered product , study vaccine , within 30 day precede dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous hepatitis B booster vaccination since administration fourth dose Infanrix hexa™ booster second year life . History intercurrent hepatitis B disease . Hepatitis B vaccination birth . Planned administration/administration vaccine foreseen study protocol period start 30 day end 30 day hepatitis B vaccine challenge dose . Administration immunoglobulins and/or blood product within three month precede challenge dose plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior challenge dose HBV vaccine . History reaction hypersensitivity likely exacerbate component hepatitis B vaccine , evidence hypersensitivity previous immunisation vaccine contain hepatitis B component . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>immune response</keyword>
	<keyword>Engerix-B™Kinder</keyword>
	<keyword>Persistence</keyword>
	<keyword>challenge dose</keyword>
</DOC>